Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort

About this update from Charles River Laboratories International, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1245,"height":326,"url":"https://media.zenfs.com/en/business-wire.com/e31c7546c10bcda06c9262554961c999"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cRXjAYG0JxKlV.jDLr0H4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e31c7546c10bcda06c9262554961c999","width":960,"height":251},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pk4zi5iHXbMfLHuHek4XbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e31c7546c10bcda06c9262554961c999","width":1200,"height":314}},"lazy":false},{"type":"text","content":"Final 2025 global cohort onboarding, with applications now open for 2026","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Mass., December 11, 2025--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as well as a comprehensive ecosystem of discovery, development, and manufacturing capabilities, to expedite the development of technologies and life-changing therapies for patients in need.","length":589,"tagName":"p"},{"type":"text","content":""The CIP’s success shows how effectively it attracts top talent and promotes innovation," said Kerstin Dolph, Corporate Senior Vice President of Global Manufacturing, Charles River. "By establishing a strong foundation for commercial viability, the CIP is helping participants advance life-saving therapeutics and transform innovative ideas into real-world impact."","length":385,"tagName":"p"},{"type":"text","content":"The CIP cohort of six companies comprises four advanced therapy developers: CureAge Therapeutics, InterAct Therapeutics, Jaan Biotherapeutics, Inc., and Kopra Bio, plus two enabling technology developers: W.R. Grace & Co. (Grace), and HTLab AG’s Biowerkli. Program participants benefit from tailored mentorship, consultative regulatory and quality expertise, fit-for-purpose training initiatives,...

More updates from Charles River Laboratories International, Inc.